Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2018

View Archived Issues

FDA accepts Selecta Biosciences' IND for SEL-403

Longevity Biotech awarded NIH contract to develop 5A apoA-I mimetic peptide for severe asthma

Patient enrollment ongoing in phase I study of cytomegalovirus vaccines mRNA-1647 and mRNA-1443

Sarepta Therapeutics begins enrollment in phase I study of SRP-5051

Simultaneous deletions of genes on two CDRs cooperate to induce B-cell abnormalities in mice

Sangamo, Pfizer to develop zinc finger protein gene therapy for ALS

Allergan exercises options for DARPin product candidates

FDA clears Palatin's IND for ulcerative colitis drug candidate

VistaGen Therapeutics' AV-101 awarded FDA fast track designation

Acacia Pharma announces FDA acceptance of NDA filing for Baremsis

HDAC11 found to be a therapeutic target for multiple myeloma

Expansion Therapeutics closes series A financing

Opthea commences phase Ib/IIa study of OPT-302 in DME

Asana BioSciences cleared to begin clinical testing of ASN-007

Paratek reviews progress in product pipeline

VenatoRx's VNRX-5133 given QIDP and fast track designations in U.S.

Jiangsu Hengrui Medicine patents ROM-K inhibitors

Rasna Therapeutics reports follow-up phase II data on actinomycin D in AML

Eli Lilly & Co. divulges new IDH1 mutant inhibitors

Bristol-Myers Squibb identifies EDL inhibitors

H1 receptor antagonists presented by Shenzhen Targetrx Biotechnology

Medshine Discovery divulges novel PKB inhibitors

Arvinas and Pfizer establish research collaboration and license agreement

FDA grants breakthrough therapy designation to Promacta for first-line use in severe aplastic anemia

EMA accepts CMA application for avacopan for ANCA-associated vasculitis

Phase Ib/II data on TAK-659 presented for relapsed/refractory AML

Five Prime submits IND for immuno-oncology therapy FPA-150

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....